Patents by Inventor Lynn E. Murry
Lynn E. Murry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030044812Abstract: The invention provides compositions and novel cDNAs that co-express with cell differentiation gene transcripts induced by retinoic acid. The invention also provides expression vectors, host cells, proteins encoded by the cDNAs and antibodies which specifically bind the proteins. The invention also provides methods for the diagnosis, prognosis and treatment of and disorders associated with cell and tissue development and differentiation.Type: ApplicationFiled: January 18, 2002Publication date: March 6, 2003Inventors: Michael G. Walker, Peter J. van der Spek, Andreas Kremer, Lynn E. Murry
-
Publication number: 20020155538Abstract: The present invention provides a novel endothelial growth factor (NVR) and polynucleotides which identify and encode NVR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NVR and a method for producing NVR. The invention also provides for agonists, antibodies, or antagonists specifically binding NVR, and their use, in the prevention and treatment of diseases associated with expression of NVR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NVR for the treatment of diseases associated with the expression of NVR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NVR.Type: ApplicationFiled: January 9, 2002Publication date: October 24, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Publication number: 20020123054Abstract: The invention provides a cDNA which encodes human angiopoietin. It also provides for the use of the cDNA and protein in the diagnosis, prognosis, treatment and evaluation of therapies for cardiovascular, neoplastic, immune and reproductive disorders. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.Type: ApplicationFiled: July 2, 2001Publication date: September 5, 2002Inventors: Jennifer L. Hillman, Gina A. Gorgone, Chandra Arvizu, Lynn E. Murry
-
Publication number: 20020107385Abstract: The present invention provides polynucleotides that identify and encode two human steroid binding proteins (hSBP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding hSBP polypeptides. The invention also provides for the use of substantially purified hSBP polypeptides, antagonists, and nucleotide sequences (e.g., antisense sequences) in pharmaceutical compositions for the treatment of diseases associated with the expression of hSBP, specifically in the treatment of breast cancer. The invention also describes diagnostic assays for the detection of breast cancer in a susceptible or affected patient. The diagnostic assays utilize compositions comprising the polynucleotides encoding hSBP polypeptides or the complements thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding hSBP or anti-hSBP antibodies that specifically bind to an hSBP polypeptide.Type: ApplicationFiled: August 21, 2001Publication date: August 8, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Ingrid E. Akerblom, Jennifer L. Hillman, Lynn E. Murry, Surya K. Goli, Phillip R. Hawkins
-
Publication number: 20020102684Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.Type: ApplicationFiled: June 6, 2001Publication date: August 1, 2002Applicant: Incyte Phrmaceuticals, Inc.Inventors: Phillip R. Hawkins, Lynn E. Murry
-
Publication number: 20020090679Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.Type: ApplicationFiled: August 24, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Publication number: 20020081699Abstract: The present invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing NHLP and for treating or preventing disorders associated with expression of NHLP.Type: ApplicationFiled: November 19, 2001Publication date: June 27, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Lynn E. Murry
-
Publication number: 20020082211Abstract: The invention provides a cDNA which encodes human presenilin variant. It also provides for the use of the cDNA and protein in the diagnosis, prognosis, treatment and evaluation of therapies for cancer or neurodegenerative or immune disorders. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.Type: ApplicationFiled: June 29, 2001Publication date: June 27, 2002Inventors: Chandra Arvizu, Lynn E. Murry, Matthew R. Kaser
-
Publication number: 20020064792Abstract: The present invention is a computerized storage and retrieval system for genetic information and related annotated information. The data of the system is stored in a relational database which interfaces with public databases to allow analysis both within the database of the invention and between information within that database and external public databases. The sequence data is edited before entry into the system, and is stored in a curated, functional clustering organization. The information associated with the data is stored in an expression database that is linked to the storage of the sequence data.Type: ApplicationFiled: September 19, 2001Publication date: May 30, 2002Inventors: Stephen E. Lincoln, Tod M. Klingler, Janice Au-Young, Y. Tom Tang, Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Phillip R. Hawkins, Lynn E. Murry, Angelo M. Delegeane, Wendy B. Levine, Jennifer L. Hillman, Surya K. Goli, Christina M. Altus, Olga Bandman, Samuel T. LaBrie, Purvi Shah
-
Publication number: 20020001827Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.Type: ApplicationFiled: February 12, 2001Publication date: January 3, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
-
Patent number: 6319701Abstract: The present invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing NHLP and for treating or preventing disorders associated with expression of NHLP.Type: GrantFiled: December 15, 1998Date of Patent: November 20, 2001Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Lynn E. Murry
-
Patent number: 6303297Abstract: The present invention is a computerized storage and retrieval system for genetic information and related annotated information. The data of the system is stored in a relational database which interfaces with public databases to allow analysis both within the database of the invention and between information within that database and external public databases. The sequence data is edited before entry into the system, and is stored in a curated, functional clustering organization. The information associated with the data is stored in an expression database that is linked to the storage of the sequence data.Type: GrantFiled: November 13, 1997Date of Patent: October 16, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Steve E. Lincoln, Tod M. Klingler, Janice Au-Young, Y. Tom Tang, Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Phillip R. Hawkins, Lynn E. Murry, Angelo M. Delegeane, Wendy B. Levine, Jennifer L. Hillman, Surya K. Goli, Christina M. Altus, Olga Bandman, Samuel T. LaBrie, Purvi Shah
-
Publication number: 20010012515Abstract: The invention provides a human nucleotide pyrophosphohydrolase-2 (NTPPH-2) and polynucleotides which identify and encode NTPPH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-2.Type: ApplicationFiled: January 9, 2001Publication date: August 9, 2001Inventors: Holly Magna, Paul Schaffer, Michael Lawton, Sue Yocum, Peter Mitchell, Nancy Hutchinson, Lynn E. Murry
-
Patent number: 6251389Abstract: The invention provides a human nucleotide pyrophosphohydrolase-2 (NTPPH-2) and polynucleotides which identify and encode NTPPH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-2.Type: GrantFiled: October 28, 1999Date of Patent: June 26, 2001Assignee: Incyte Genomics, Inc.Inventors: Holly Magna, Paul Schaffer, Michael Lawton, Sue Yocum, Peter Mitchell, Nancy Hutchinson, Lynn E. Murry
-
Patent number: 6238666Abstract: The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a human rantes homolog (PTEC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.Type: GrantFiled: September 14, 1999Date of Patent: May 29, 2001Assignee: Incyte Genomics, Inc.Inventors: Phillip R. Hawkins, Olga Bandman, Lynn E. Murry
-
Patent number: 6204021Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.Type: GrantFiled: January 31, 1997Date of Patent: March 20, 2001Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
-
Patent number: 6204372Abstract: The present invention provides a novel human tubby homolog (NHT) and polynucleotides which identify and encode NHT. The invention also provides expression vectors, host cells, agonists, antibodies, or antagonists. The invention also provides methods for treating disorders associated with appetite and eating.Type: GrantFiled: March 6, 1997Date of Patent: March 20, 2001Assignee: Incyte Genomics, Inc.Inventors: Samuel T. Labrie, Preeti Lal, Lynn E. Murry
-
Patent number: 6143544Abstract: The invention provides a new human lysophospholipase (JHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.Type: GrantFiled: June 19, 1997Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry
-
Patent number: 6124095Abstract: The invention provides a human nucleotide pyrophosphohydrolase-2 (NTPPH-2) and polynucleotides which identify and encode NTPPH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-2.Type: GrantFiled: December 22, 1997Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Holly Magna, Paul Schaffer, Michael Lawton, Sue Yocum, Peter Mitchell, Nancy Hutchinson, Lynn E. Murry
-
Patent number: 6114123Abstract: The invention provide a mammalian nucleic acid molecule and fragments thereof. It also provides for the use of the mammalian nucleic acid molecule for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with gene expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecule.Type: GrantFiled: June 14, 1999Date of Patent: September 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Lynn E. Murry, Tom Y. Tang, Mariah R. Baughn